Healthcare Services

Chronic Sialorrhea Industry Expansion Forecast Showing Market Size of $1.02 Billion by 2030 at 6% CAGR

March 31, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Chronic Sialorrhea Market Expected To Change Between 2026 And 2030?

The chronic sialorrhea market size has experienced significant growth in recent years. It is projected to increase from $0.76 billion in 2025 to $0.81 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.2%. This historical growth can be attributed to the rising prevalence of neurological disorders, more extensive clinical use of anticholinergic medications, the expansion of rehabilitation services, enhanced diagnosis of salivary disorders, and an uptick in specialty clinic treatments.

The chronic sialorrhea market is projected to experience robust expansion over the coming years, anticipated to reach $1.02 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. This anticipated growth during the forecast period is fueled by several factors, including a rise in approvals for novel injectable treatments, a heightened emphasis on home-based care options, the proliferation of assistive oral devices, an expanding elderly demographic, and increased financial commitments to managing neurological disorders. Key trends characterizing this period encompass a surge in the application of botulinum toxin therapies, greater uptake of non-invasive management strategies, an intensified focus on sialorrhea care connected to neurological conditions, the broadening availability of assistive medical devices, and a stronger commitment to enhancing patient quality of life.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21149&type=smp

What Underlying Factors Are Accelerating The Growth Of The Chronic Sialorrhea Market?

The chronic sialorrhea market is projected to expand due to increasing research and development efforts. These activities involve structured endeavors aimed at developing novel innovations or enhancing current products, technologies, or processes through scientific investigation and trials. The expansion of research and development is fueled by the continuous need for innovation, enabling organizations to develop advanced solutions and maintain a competitive edge in dynamic markets. For chronic sialorrhea, research and development is crucial as it facilitates the discovery and refinement of specific therapies, delivery methods, and diagnostic techniques, leading to more effective reduction of excessive drooling and a better quality of life for patients. For instance, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government’s net spending on research and development (R&D) increased to £17.4 billion ($22.1 billion) in 2023, up from £16.1 billion ($20.45 billion) in 2022, marking an 8.2% rise. Consequently, the rise in research and development activities is a key factor propelling the chronic sialorrhea market’s growth.

How Is The Chronic Sialorrhea Market Structured Across Different Segments?

The chronic sialorrhea market covered in this report is segmented –

1) By Treatment Type: Pharmacological Treatments, Botulinum Toxin Injections, Surgical Interventions, Medical Devices And Assistive Therapies

2) By Route Of Administration: Oral Medications, Injectable Treatments, Topical Applications

3) By Patient Population: Pediatric Patients, Adult Patients

4) By End-User: Hospitals And Specialty Clinics, Rehabilitation Centers, Homecare Settings

Subsegments:

1) By Pharmacological Treatments: Anticholinergic Medications, Antidepressants, Alpha-Adrenergic Agonists, Salivary Gland Modulators

2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox), Botulinum Toxin Type B (Myobloc), Localized Salivary Gland Injections

3) By Surgical Interventions: Sialendoscopy, Salivary Gland Duct Dilation Or Stenting, Parotid Duct Surgery, Submandibular Gland Removal (Sialadenectomy)

4) By Medical Devices And Assistive Therapies: Oral Dryness Devices, Salivary Stimulation Devices, Lip And Mouth Exercises, Artificial Salivary Glands

Which Market Trends Are Creating New Opportunities In The Chronic Sialorrhea Market?

Leading firms in the chronic sialorrhea market are prioritizing the creation of novel therapies, including oral solutions, to boost patient adherence and offer non-invasive options for pediatric chronic sialorrhea management, thereby enhancing both safety and effectiveness while minimizing adverse effects. An oral solution refers to a liquid medicine prepared for consumption by mouth, where the active compound is dissolved in a solvent, facilitating simple intake. For example, in February 2023, Proveca Pharma Ltd., a pharmaceutical company from the UK, introduced Sialanar (glycopyrronium bromide) in France to address severe chronic sialorrhea in children diagnosed with neurological disorders. A prominent attribute of this product is its liquid composition, crafted for straightforward administration and precise dosage, rendering it especially advantageous for pediatric patients encountering difficulties with solid medicines. It presents a proven safety and effectiveness record, contributing to an enhanced quality of life through the reduction of excessive drooling, a frequent issue in neurodevelopmental conditions such as cerebral palsy.

Which Major Players Dominate The Chronic Sialorrhea Market?

Major companies operating in the chronic sialorrhea market are Pfizer Inc, Ipsen Pharmaceuticals Inc, Aurobindo Pharma Limited, Hugel Inc, Medy-Tox Inc, Granules India Limited, US WorldMeds LLC, Merz Therapeutics GmbH, Taj Pharma India Limited, Teva Pharmaceutical Industries Ltd, Bayer AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Lundbeck A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Novartis AG, Astellas Pharma Inc, Viatris Inc, Sandoz International GmbH, Proveca Limited, NeuroHealing Pharmaceuticals Inc, Solstice Neurosciences Inc, Gufic Biosciences Limited

Read the full chronic sialorrhea market report here:

https://www.thebusinessresearchcompany.com/report/chronic-sialorrhea-global-market-report

Which Region Is Projected To Dominate The Chronic Sialorrhea Market During The Forecast Period?

North America was the largest region in the chronic sialorrhea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic sialorrhea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chronic Sialorrhea Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21149&type=smp

Browse Through More Reports Similar to the Global Chronic Sialorrhea Market 2026, By The Business Research Company

Nasal Polyps Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/nasal-polyps-treatment-global-market-report

Nasal Splints Global Market Report

https://www.thebusinessresearchcompany.com/report/nasal-splints-global-market-report

Rhinoplasty Global Market Report

https://www.thebusinessresearchcompany.com/report/rhinoplasty-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795